YM155 (Sepantronium Bromide)

For research use only.

Catalog No.S1130

110 publications

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 447 In stock
USD 770 In stock
USD 1270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's YM155 (Sepantronium Bromide) has been cited by 110 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 M4\5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm3NkBp MWTEUXNQ NXj0OnB1UUN3ME2wMlAxQSEEsTCwMlAxODlizszN MXmyOVY2QTd|MR?=
M-07e MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrzO|IhcA>? MUHEUXNQ MlfWTWM2OD1yLkC0NEDDuSByLkCxN{DPxE1? M3jNRVI2PjV7N{Ox
THP-1 M{HYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHDTFY4OiCq Ml;DSG1UVw>? Mn;LTWM2OD1yLkC1NUDDuSByLkCxN{DPxE1? M3\CR|I2PjV7N{Ox
CMK NYW3SI1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPRWmZjPzJiaB?= NF\hVIlFVVOR NYe5e213UUN3ME2wMlA2OyEEsTCwMlAxQSEQvF2= MXKyOVY2QTd|MR?=
MV4-11 M4\lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzlb2Q4OiCq NGDJR2FFVVOR M3PRVWlEPTB;MD6wOVUhyrFiMD6wNlgh|ryP MoDBNlU3PTl5M{G=
AML-193 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfWO|IhcA>? NIXzRmhFVVOR M2q0NWlEPTB;MD60OlIhyrFiMD6wOlAh|ryP MkLwNlU3PTl5M{G=
HL-60 NYC0VoF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[3O|IhcA>? NHfaWIJFVVOR MWTJR|UxRTBwMECxJOKyKDBwMECwNkDPxE1? MXiyOVY2QTd|MR?=
ML-2 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnl[3l6PzJiaB?= M3nxd2ROW09? NUCwdWdKUUN3ME2wMlAxQSEEsTCwMlAxOiEQvF2= MYqyOVY2QTd|MR?=
OCI/AML3 M3LKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK0O|IhcA>? NX3teolnTE2VTx?= NVvXNmxFUUN3ME2wMlAyOSEEsTCwMlAxOiEQvF2= M36yUlI2PjV7N{Ox
HEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M320UFczKGh? M3fiXWROW09? NYXteoZUUUN3ME2wMlU2QSEEsTCwMlA{QCEQvF2= M{PVS|I2PjV7N{Ox
ME-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NkBp MVTEUXNQ Moi1TWM2OD1yLk[4OEDDuSByLkG3PUDPxE1? MUSyOVY2QTd|MR?=
THP-1 M3PPe2Fxd3C2b4Ppd{BCe3OjeR?= NFf5NJEyyqEQvF2= NGPjd4c4OiCq NHrtXXFFVVOR NGHlXHNqdmS3Y3XzJIFxd3C2b4Ppdy=> M3;VRVI2PjV7N{Ox
M-07e M1TJeWZ2dmO2aX;uJGF{e2G7 NXTWfmh3OOLCk{JCpO69VQ>? M4q3OFczKGh? M4e5WWROW09? NUTPU3JKcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NXTsSlZEOjV4NUm3N|E>
THP-1 NX\CVnFUTnWwY4Tpc44hSXO|YYm= MXKw5qCUOcLizszN MkPzO|IhcA>? M4Pzb2ROW09? MmfJbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NGnKfXgzPTZ3OUezNS=>
CMK MXzGeY5kfGmxbjDBd5NigQ>? NUS4fXdpOOLCk{JCpO69VQ>? NHvTO4w4OiCq NVzIbHJxTE2VTx?= M3n1b4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= M1PWZ|I2PjV7N{Ox
AML-193 MknySpVv[3Srb36gRZN{[Xl? MXSw5qCUOcLizszN MWe3NkBp MXfEUXNQ NIKxSW1qdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MofuNlU3PTl5M{G=
Kasumi-1 M{PtRmZ2dmO2aX;uJGF{e2G7 M2Li[FDjiJNzwrFOwG0> NGrGTJA4OiCq M3TWSWROW09? NEexUZZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MmmxNlU3PTl5M{G=
MV4-11 M2DqNGZ2dmO2aX;uJGF{e2G7 MknvNQKBmzIEoN88US=> NXXK[XpPPzJiaB?= MnXNSG1UVw>? MoDabY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= MYmyOVY2QTd|MR?=
MUG-Chor  NEPmdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlflNE02KM7:TR?= M3nY[VI1NzR6IHi= NGXWUHhKSzVyPUeuNFXjiImwTTDmc5IhPDiq MXyyOVY1ODF6NR?=
U-CH1  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrDW2lIOC13IN88US=> MXqyOE81QCCq NEHQXmNKSzVyPUmuNFPjiImwTTDmc5IhPDiq NH7GdVIzPTZ2MEG4OS=>
KATOIII NXO0VIpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PlW|ExNzJyIH7N NFXDPG41QCCq NGHjZoVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFjrboUzPTZ|NUC1OS=>
AGS  MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH0WnYyOC9{MDDuUS=> M3zBN|Q5KGh? M2jG[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmTZNlU3OzVyNUW=
SACC-83 MVzGeY5kfGmxbjDBd5NigQ>? M1;yTVUhdk1? MXu0PEBp NXfBZWEz\GWlcnXhd4V{KG63Y3zlZZIh\XiycnXzd4lwdiCxZjDITWYuOc7z M{[0RlI2PDh3NkO1
INA-6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzXT5NlOC13MECgcm0> NEDZbXc1QCCq MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NEHYemIzPTJ7Nkm3PC=>
U-266 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWwMVUxOCCwTR?= NELHNWY1QCCq MkXCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFrvO4YzPTJ7Nkm3PC=>
MOLP-8 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u4cFAuPTByIH7N MnXSOFghcA>? MmPqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NULmSWQzOjV{OU[5O|g>
HG-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nabVAuPTByIH7N MYW0PEBp Mne1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4q3[FI2Ojl4OUe4
NCI-H929 NWnzU3YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMVUxOCCwTR?= MVq0PEBp M1WyNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoDtNlUzQTZ7N{i=
OPM-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M133XlAuPTByIH7N NFnNNIM1QCCq M33NSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWKyOVI6Pjl5OB?=
L-363 M2D1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPONE02ODBibl2= M3n0T|Q5KGh? M1[0UIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWO1Z4ZPOjV{OU[5O|g>
MOLP-2 NH3WOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrnNYNIOC13MECgcm0> MmXlOFghcA>? MoHhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVWyOVI6Pjl5OB?=
KMS-12-BM NIG4NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKwMVUxOCCwTR?= MlPlOFghcA>? NIXwN|hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXiyOVI6Pjl5OB?=
SK-MM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf2NE02ODBibl2= M2G4bVQ5KGh? MknpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGXSNokzPTJ7Nkm3PC=>
U-266 M2LmcmFxd3C2b4Ppd{BCe3OjeR?= MW[wMVUxKG6P M2L5eVI1KGh? MUTpcoR2[2W|IHHwc5B1d3Orcx?= MmLtNlUzQTZ7N{i=
INA-6  NH7UZpNCeG:ydH;zbZMhSXO|YYm= MYiwMVUxKG6P MlvHNlQhcA>? NIPNeJFqdmS3Y3XzJIFxd3C2b4Ppdy=> MYWyOVI6Pjl5OB?=
MCF7 M{D3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG1O|IhcA>? M2L1UmlEPTB;MUOgxtEhPiCwTR?= NUP3[W5MOjV{MkCyNlU>
MCF7-TamR6 NImyOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2xZWFlPzJiaB?= MWPJR|UxRThiwsGgOkBvVQ>? M4TCXFI2OjJyMkK1
MCF7-TamR7 M1[4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYq3NkBp MUfJR|UxRThiwsGgN{BvVQ>? MkXRNlUzOjB{MkW=
MCF7-TamR8 NVvhPHk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;NUlczKGh? MkfVTWM2OD1zNTFCtUA3KG6P M{\FTFI2OjJyMkK1
MCF7-TamC3 NHfJXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe3NkBp MUDJR|UxRTZiwsGgN{BvVQ>? NYmwbmExOjV{MkCyNlU>
MCF7-TamC6 NVfJUlRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT5O|IhcA>? MmPXTWM2OD14INMxJFAvOSCwTR?= M2HHcFI2OjJyMkK1
MDA-MB-231 NVjabZhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3NkBp M17PU2lEPTB;NTFCtUAyKG6P NXnKNFFmOjV{MkCyNlU>
SK-BR-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\3O|IhcA>? MYXJR|UxRTdiwsGgNE4{KG6P MWmyOVIzODJ{NR?=
Eca109 M162N2Z2dmO2aX;uJGF{e2G7 M3L5XlEuPTBibl2= NYi2d4lQPDhiaB?= M3P3[2ROW09? M2XjN5N2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3HmNVI2OTN7M{m1
TE13 M3HtWmZ2dmO2aX;uJGF{e2G7 NEO2cJoyNTVyIH7N M1vGUVQ5KGh? Mk\oSG1UVw>? M3;WOJN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NInyZXQzPTF|OUO5OS=>
Eca109 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nRSFAuOTByIH7N M4XQfVI1NzR6IHi= MnjPSG1UVw>? NV;HeWZP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYDUWXpiOjVzM{mzPVU>
TE13 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmniNE0yODBibl2= NXv5UZlwOjRxNEigbC=> NVWwN3lvTE2VTx?= Mlrl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MU[yOVE{QTN7NR?=
MT-3 NV3NdXVNU2mwYYPlJGF{e2G7 M1jveVczKGh? M37Oc2ROW09? MYfJR|UxRTJwOE[gxtEhOC53NDDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> MXeyOFg3PjV6NR?=
MDA-MB-468 M3rlVmtqdmG|ZTDBd5NigQ>? NGex[FI4OiCq MmexSG1UVw>? NF73dHpKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? MlHoNlQ5PjZ3OEW=
SUM-159 NYfTVVVzU2mwYYPlJGF{e2G7 MWi3NkBp MWnEUXNQ NVnPNIN1UUN3ME2xMlczKMLzIECuN|Mhdk1iZn;yJGRTPCCneIDy[ZN{cW:w NGLi[nozPDh4NkW4OS=>
MT-3 NGDZcWVMcW6jc3WgRZN{[Xl? NEHDTpk4OiCq M2fCNWROW09? NXrJbGRnUUN3ME21OE4yOSEEsTC0MlMzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= NI\F[oUzPDh4NkW4OS=>
MDA-MB-468 MWPLbY5ie2ViQYPzZZk> NFmyVJY4OiCq M{L4cGROW09? NX;wfox{UUN3ME2wMlA4KMLzIECuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w NGq0ToozPDh4NkW4OS=>
SUM-159 NYrMdHFVU2mwYYPlJGF{e2G7 NHfGNG44OiCq NHnFR5RFVVOR M3XrW2lEPTB;NkmuOEDDuSB2LkKzJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? M2rD[|I1QDZ4NUi1
MT-3 + NAC MmnlT4lv[XOnIFHzd4F6 NVjQdGt4PzJiaB?= MYjEUXNQ NVe1XoRYUUN3ME21Ok4zKMLzIEKuNFchdk1iZn;yJGRTPSCneIDy[ZN{cW:w NES4NXYzPDh4NkW4OS=>
MT-3 + SB203580 MWrLbY5ie2ViQYPzZZk> M3z4b|czKGh? MmfFSG1UVw>? M2joVWlEPTB;M{iuOFEhyrFiNT6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MnqyNlQ5PjZ3OEW=
DB NYfXVZRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHkVIR2OTBibl2= M4C0OlI1KGh? NFfBSYNFVVOR NXr1Zo1zcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NUn3RpVnOjR2OE[1PVU>
SU-DHL-8 M3zXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnOcplNOTBibl2= NWK3O4V4OjRiaB?= Mnu0SG1UVw>? NIf3SGxqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MYqyOFQ5PjV7NR?=
WSU-DLCL2 M3HpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNEBvVQ>? MUGyOEBp M17LWmROW09? NGHBfI9qdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MmHJNlQ1QDZ3OUW=
ACC-2 NITXe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3vNo4xNTFyMDDuUS=> M2PrUlI1KGh? M{XrWIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIHPN5gzPDN5MEm5OS=>
ACC-2 M3TIZmFxd3C2b4Ppd{BCe3OjeR?= M3[2eFAuOjBibl2= MlLZNlQhcA>? NYfmZ4s1cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXWyOFM4ODl7NR?=
ACC-2 MW\GeY5kfGmxbjDBd5NigQ>? MXiwMVIxKG6P NF\FXpgzPCCq M3TaSYlv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL NID6clQzPDN5MEm5OS=>
BFTC905 NESzcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jRcVAuOTByMDDuUS=> NVX6WnZmPDhiaNMg NXi2SWhrTE2VTx?= M3L3WWlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NW\1PGVXOjR{OUe2OFQ>
T24 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfiNE0yODByIH7N M1fUXVQ5KGkEoB?= NHLKdm5FVVOR MX;JR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3rUdFI1Ojl5NkS0
TSGH8301  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C4S|AuOTByMDDuUS=> M1LMblQ5KGkEoB?= NIC0[IVFVVOR MWDJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXzETlR6OjR{OUe2OFQ>
BFTC909 NFHUSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XTTFAuOTByMDDuUS=> NH3EUYM1QCCqwrC= MVPEUXNQ NWG2eIdMUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmDkNlQzQTd4NES=
BFTC905 MW\BdI9xfG:|aYOgRZN{[Xl? NWfvOVNsOjBibl2= NVLZSWlKPDhiaB?= Mn:1SG1UVw>? NHuzcGJqdmS3Y3XzJIFxd3C2b4Ppdy=> NIq5d4IzPDJ7N{[0OC=>
BFTC905 M{TLcmZ2dmO2aX;uJGF{e2G7 MmHsNlAhdk1? MUm0PEBp MUDEUXNQ MWHk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{Si2LSR?= MWGyOFI6PzZ2NB?=
A2780p M4TPPGZ2dmO2aX;uJGF{e2G7 MWGwMVExOCCwTR?= NEm3RnczPCCq NVvnUpd[TE2VTx?= MVrpcoR2[2W|IGP1dpZqfmmwIHTve45z\We3bHH0bY9vyqB? NHe4TFIzPDJ4Mki3OS=>
A2780cis NWj2cXZsTnWwY4Tpc44hSXO|YYm= NVz2NlNFOC1zMECgcm0> NWjz[IR2OjRiaB?= M4XtbWROW09? MkfKbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi M2H5blI1OjZ{OEe1
A2780p NVvybYE2SXCxcITvd4l{KEG|c3H5 NIP4cFg2NTFyMDDuUS=> MnzNNlQwPDhiaB?= NVr3[21YTE2VTx?= MoPybY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MmC4NlQzPjJ6N{W=
A2780cis M2rrdWFxd3C2b4Ppd{BCe3OjeR?= NHjKfmk2NTFyMDDuUS=> MX[yOE81QCCq NIi3VYdFVVOR MVjpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy M3HBVlI1OjZ{OEe1
SH-SY5Y MofURZBweHSxc3nzJGF{e2G7 MV6xM|ExNzFyMDFCuW0> NELHbGs4OiCq NXHTXYpzTE2VTx?= MX7pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mm\ZNlQzPTR3NkC=
HL-60 NYjMeXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof1O|LDqGh? NX;zcolmTE2VTx?= M3OxSGlEPTB;MD6zJI5O MkTMNlM3OTh6NkK=
U937  Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7WO|LDqGh? MULEUXNQ Mn;6TWM2OD1yLkigcm0> MXOyN|YyQDh4Mh?=
HL-60  NVjEbW83TnWwY4Tpc44hSXO|YYm= NWm1V2NZOcLizszN NX75botDPi9zMj:yOEBp M4e0RWROW09? NVW5SFZjcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhe3W{dnn2bY4> MoizNlM3OTh6NkK=
U937  MVfGeY5kfGmxbjDBd5NigQ>? NGnyRZcyyqEQvF2= MWS2M|EzNzJ2IHi= MYTEUXNQ M{Xo[olvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu MnfDNlM3OTh6NkK=
HL-60 NIHsPVdCeG:ydH;zbZMhSXO|YYm= MlzNNE4yNzFizszN M13tUFghcA>? NVnNNZZqTE2VTx?= M2HIcYlv\HWlZYOgZZBweHSxc3nz NG\UToszOzZzOEi2Ni=>
Sk-NEP-1  NFjlZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLHNU0yODByMDDuUS=> MWSyOEBp MVXEUXNQ MVXJR|UxRTFyMDDuUS=> NUK4cm1iOjN{Nke2PVk>
SK-NEP-1  MnfERZBweHSxc3nzJGF{e2G7 NIXweG02OC9zMECgcm0> MmW3NVIwOjRiaB?= Mn7DSG1UVw>? M33h[Ylv\HWlZYOgZZBweHSxc3nz MXWyN|I3PzZ7OR?=
TC-32 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTwVGs3OC5zLUGwNFAhdk1? NUXPZZJoTUN3ME2zMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGrDR4szOjl4MUe2Ny=>
TC-71 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljpNE4yNTFyMECgcm0> NFTiUYpGSzVyPUWuO{BvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHP3bVIzOjl4MUe2Ny=>
SK-ES-1 M3X0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILMXGgxNjFvMUCwNEBvVQ>? MnPESWM2OD1{Lkigcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVSyNlk3OTd4Mx?=
RD-ES MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP3NE4yNTFyMECgcm0> NUTS[YY2TUN3ME22MlIhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXiyNlk3OTd4Mx?=
HEK293 NIHIZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3myVFAvOS1zMECwJI5O M1LONmVEPTB;MkOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1XOW|IzQTZzN{[z
M059J Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmyO|hQOC13MDDuUS=> NFi0OVY1QCCq NF\OXVhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1Lq[VIzPzdyMUGw
M059K NHrUPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXBNE02OCCwTR?= M1LwNFQ5KGh? M3Hh[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3fsVlIzPzdyMUGw
M059J MX7BdI9xfG:|aYOgRZN{[Xl? M1\vdVMxKG6P NVj3UpBMOjRiaB?= NFXBcnpqdmS3Y3XzJIFxd3C2b4Ppdy=> MWCyNlc4ODFzMB?=
M059K M32yeGFxd3C2b4Ppd{BCe3OjeR?= M1f0[FMxKG6P M1zPc|I1KGh? NX;xO5FTcW6mdXPld{BieG:ydH;zbZM> M{LKOVIzPzdyMUGw
PANC-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2zNE4xOS1zMECwJI5O M1fxRlQ5KGh? MlnHTWM2OD1|Lk[5JI5O NXLV[YgzOjJ5MkO4O|E>
MIAPaCa-2 M4jSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXaNE4xOS1zMECwJI5O NXfXPY97PDhiaB?= MVjJR|UxRTJ7LkO2JI5O NYewWZFJOjJ5MkO4O|E>
BxPC-3 M2m1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3lV2kxNjBzLUGwNFAhdk1? Ml\BOFghcA>? NHLvfW1KSzVyPUOwMlI3KG6P MXyyNlczOzh5MR?=
PANC-1 M1ywV2Z2dmO2aX;uJGF{e2G7 NF7zNZYxNTFyMECgcm0> MV[yOEBp M1LkU4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> NH\h[WwzOjd{M{i3NS=>
MIAPaCa-2 M3TBTmZ2dmO2aX;uJGF{e2G7 NYn0bYl1OC1zMECwJI5O MW[yOEBp MVXpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= M3PX[VIzPzJ|OEex
BxPC-3 NXHaToRFTnWwY4Tpc44hSXO|YYm= Mkj2NE0yODByIH7N M1PDPFI1KGh? M4H3colv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> MUOyNlczOzh5MR?=
RPMI-7951 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TMeWdKPTB;Mz6yJI5O M3HhRVIyPzN5NUCy
SK-MEL-5 M4jEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHruXVRIUTVyPUSuNkBvVQ>? NYXaWIRHOjF5M{e1NFI>
A375 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnQOXVIUTVyPU[uN{BvVQ>? Mnu0NlE4Ozd3MEK=
SK-MEL-28 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzOSo8zT0l3ME23MlYhdk1? M3HJclIyPzN5NUCy
SK-MEL-2 NWG5OmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHHTVUxRTFzIH7N MnfINlE4Ozd3MEK=
DB MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PoV|Q5yqCq M{\u[2dKPTB;Mz61JI5O MmfkNlEzOzd3MEi=
Pfeiffer M17VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi0POKhcA>? MV\HTVUxRTNwOTDuUS=> MYiyNVI{PzVyOB?=
SU-DHL-5 NFHwNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HLUVQ5yqCq NFTSdW5IUTVyPUCuNlMhdk1? Mn;1NlEzOzd3MEi=
SU-DHL-8 M3;nSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnBOFjDqGh? MkjUS2k2OD1zLkSgcm0> MnTtNlEzOzd3MEi=
WSU-DLCL-2 NYfQc4Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;KdVQ5yqCq Mnq4S2k2OD1zLkSgcm0> NW\sUG9HOjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol '6 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A
Smiles [Br-].COCC[N]1C(=[N+](CC2=CN=CC=N2)C3=C1C(=O)C4=C(C=CC=C4)C3=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID